Biogen Inc. and partner Eisai Co. Ltd. on July 29 revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.
One of the eagerly anticipated presentations at the 2021 Alzheimer’s Association International Conference in Denver and virtually is Biogen and the company’s partner Eisai on their controversial drug Aduhelm (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
BioSpace takes a look at some of the stories from the first day of the Alzheimer’s Association International Conference 2021 (AAIC).
A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
Eagle Pharmaceuticals Inc. and the University of Pennsylvania agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease.